June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
A novel isoquinoline sulfonamide protein kinase inhibitor (H-1337) produces long-lasting reduction of IOP
Author Affiliations & Notes
  • Hiroyoshi Hidaka
    D Western Therapeutics Inst, Inc, Nagoya, Japan
  • Kengo Sumi
    D Western Therapeutics Inst, Inc, Nagoya, Japan
  • Takashi Izuhara
    D Western Therapeutics Inst, Inc, Nagoya, Japan
  • Atsuko Kasai
    D Western Therapeutics Inst, Inc, Nagoya, Japan
  • Hitomi Tanimoto
    D Western Therapeutics Inst, Inc, Nagoya, Japan
  • Footnotes
    Commercial Relationships Hiroyoshi Hidaka, D. Western Therapeutics Institute, Inc. (E); Kengo Sumi, D. Western Therapeutics Institute, Inc. (E); Takashi Izuhara, D. Western Therapeutics Institute, Inc. (E); Atsuko Kasai, D. Western Therapeutics Institute, Inc. (E); Hitomi Tanimoto, D. Western Therapeutics Institute, Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5712. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hiroyoshi Hidaka, Kengo Sumi, Takashi Izuhara, Atsuko Kasai, Hitomi Tanimoto; A novel isoquinoline sulfonamide protein kinase inhibitor (H-1337) produces long-lasting reduction of IOP. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5712.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Isoquinoline sulfonamide derivatives have been known to inhibit selectively a variety of protein kinases (Hidaka et al., Biochemistry. 23: 5036-41, 1984, Hidaka et al., Methods Enzymol. 201: 328-339, 1991). Moreover, two of these inhibitors have been already succeeded to be used in the market for clinical therapies. We, here introduce another novel sulfonamide protein kinase inhibitor, H-1337, with potent IOP-lowering activity.

Methods: H-1337 (isoquinoline sulfonamide) was newly synthesized in our own laboratory and subjected to test for IOP-lowering activity and toxicological studies. Inhibition of the compound for various protein kinases were carried out by Cerep Corporation.

Results: Leucine-rich repeat kinase 2 (LRRK2) was most effectively inhibited (IC50: 0.045 μM) by H-1337. Novel LRRK2-inhibitor (H-1337) was selected after extensive screening for protein kinase inhibition including LRRK2. The structure of H-1337 was born from our discovery (Hidaka et al., J Pharmacol Exp Ther. 207: 8-15, 1978) since about 40 years ago. Many of these isoquinoline sulfonamides are still now commercially available as chemical reagents such as H-7, H-8, H-9, H-89, KN-93, ML-7 and ML-9, etc. Potent (maximum reductions were 7.3 mmHg and 4.3 mmHg after administrations of 1% and 0.3% H-1337 in rabbits and cynomolgus monkeys, respectively) and long-lasting (durations were over 14 h and 24 h in rabbits and monkeys, respectively) IOP lowering and no systemic and no ocular toxicity was observed in animal models.

Conclusions: Inhibition of LRRK2 by H-1337 is unique character. Effective and long-lasting reduction of IOP by H-1337 could be explained by this specific kinase inhibition. (See our poster about the mechanism of IOP-lowering by H-1337, which is presented in detail by Kasai et al.)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×